Oasmia Pharmaceutical AB
Oasmia considers secondary listing on NASDAQ USA
Oasmia Pharmaceutical AB 12.09.2014 08:29 Dissemination of a Adhoc News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- UPPSALA, SWEDEN - September 12, 2014. Oasmia Pharmaceutical AB (publ) is considering a secondary listing of ADR's (American Depositary Receipts) on the United States NASDAQ stock market. Uppsala, Sweden, 2014-09-12 08:29 CEST (GLOBE NEWSWIRE) -- The company has initiated the application process, as well as filed a registration statement with the United States Securities and Exchange Commission under the JOBS Act. The company's shares are currently listed on NASDAQ OMX Stockholm and the Frankfurt Stock Exchange. 'The US is the largest pharmaceutical market in the world, and now that Oasmia has its first product - Paccal Vet(R)-CA1, for treatment of cancer in dogs - on the American market, we believe that there is an increased interest in the company among American investors. A final decision for a possible secondary listing will be made later this year', commented Oasmia's CEO Julian Aleksov. Mikael Widell, Vice President Communications Mobile: +46 70 311 99 60 E-mail: mikael.widell@oasmia.com News Source: NASDAQ OMX 12.09.2014 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Oasmia Pharmaceutical AB Sweden Phone: Fax: E-mail: Internet: ISIN: SE0000722365 WKN: End of Announcement DGAP News-Service ---------------------------------------------------------------------------
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden